Provitamin D2 Compound Drug Class List

Drugs in Drug Class: Provitamin D2 Compound

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bionpharma	VITAMIN D	ergocalciferol	CAPSULE;ORAL	080704-001	Approved Prior to Jan 1, 1982	AA	RX	No	No
Puracap Pharm Llc	ERGOCALCIFEROL	ergocalciferol	CAPSULE;ORAL	204276-001	Dec 7, 2018	AA	RX	No	No
Onesource Specialty	ERGOCALCIFEROL	ergocalciferol	CAPSULE;ORAL	090455-001	Aug 3, 2010	AA	RX	No	Yes

Market dynamics and patent landscape for provitamin D2 compounds: key drugs, exclusivity clocks, and generic/biosimilar entry risk

Last updated: June 29, 2026

The provitamin D2 class is commercially centered on dihydrotachysterol (DHT), a synthetic vitamin D2 analog used in hypoparathyroidism, hypocalcemia, and related calcium-phosphate disorders. In the US, the patent landscape is largely mature, and the principal market-entry risks in most geographies shift from broad compound IP to product-specific formulation/manufacturing protections and label-driven method-of-use claims. The practical outcome is that market dynamics are driven more by payer contracting, physician familiarity, and supply continuity than by active primary-compound patent enforcement.

---

What is the provitamin D2 drug class and which products drive sales?

Featured snippet answer: The provitamin D2 drug class is dominated by dihydrotachysterol (DHT) (an analog of vitamin D2), with market activity concentrated in endocrine and calcium disorders where oral vitamin D analogs are standard therapy.

Core active ingredients within “provitamin D2”

• Dihydrotachysterol (DHT): synthetic vitamin D2 analog, prohormone activity via vitamin D pathways.
• Other “provitamin D” constructs exist in the literature and in some jurisdictions, but the commercially relevant, repeatedly referenced branded legacy products are DHT-centric.

Main therapeutic use patterns

• Hypoparathyroidism
• Post-surgical or chronic hypocalcemia
• Rickets/osteomalacia variants associated with impaired vitamin D metabolism (use depends on local label and standard of care)

Commercial structure

• Typically small-to-mid size specialty segments versus blockbuster vitamin D analogs (calcitriol, alfacalcidol).
• Repeat chronic use supports stable but price-sensitive demand.
• Competitive pressure comes from older generics and from competing vitamin D analogs on formularies.

---

What patents protect dihydrotachysterol (provitamin D2) and how is the estate structured?

Featured snippet answer: Patent protection for DHT is typically split across (1) original compound and early synthetic routes, (2) formulation/manufacturing claims, and (3) downstream medical-use claims. In most major markets, primary compound IP is expired or near-expired, leaving residual protection focused on specific dosage forms or processes.

Patent estate archetypes seen in vitamin D analogs

Because the provitamin D2 class is legacy, estates tend to be long-lived through:

1. Compound and synthesis (often earliest filings)
2. Compositions and formulations (tablet/capsule/oil-in-solution vehicles, stability improvements)
3. Manufacturing methods (crystallization, particle size control, impurity limits)
4. Medical use (indications, dosing regimens, combination therapies)
5. Regulatory exclusivities (where applicable, these do not substitute for core patent expiry)

Jurisdictional coverage pattern

• US: focus on the Orange Book-listed patents for marketed strengths/dosage forms, plus method-of-use claims where listed.
• EP: similar split, often with more extensive claim sets tied to process and formulation.
• UK/DE/FR: often show narrower enforcement after initial litigation and transfers of rights.
• EMEA and rest-of-world: may show delayed filing strategies or local process patents.

---

When does provitamin D2 compound IP lose exclusivity in the US and EU?

Featured snippet answer: For DHT, most markets show loss of exclusivity for compound-level claims due to the age of the underlying technology; remaining exclusivity usually comes from late-filed formulation/manufacturing patents tied to specific products or from protected label-specific dosing claims.

Exclusivity clock drivers

• Patent expiration: compound and process patents typically expire first, often in the 2000s-2010s era for legacy DHT.
• Regulatory exclusivity: generally does not materially extend a legacy generic timeline unless a product received a newer exclusivity-triggering status.
• Continuation and divisional filings: can extend prosecution timelines and narrow claim scopes but rarely revive compound-level protection for long beyond the earliest priority.

What “near-term exclusivity” means in practice

Even when some patents remain active, they may protect:

• only a specific dosage strength
• only a specific formulation (e.g., oil-based vs solid)
• only a specific manufacturing process These constraints reduce generic threat unless a challenger must replicate the protected process or accept label and formulation carve-outs.

---

How many patents cover dihydrotachysterol products and what is the typical claim inventory?

Featured snippet answer: Claim inventories for DHT products usually concentrate into a modest set: a few composition patents and a few process patents, with fewer late-stage broad medical-use claims that survive scrutiny and listing in major markets.

Typical listing composition

• Drug substance claims: usually mostly expired in mature generics.
• Drug product claims: more likely to remain active due to reformulations.
• Use claims: fewer, often tied to an indication rather than the general vitamin D pathway.

What to expect in a competitive patent map

• A generic entrant can often design around a formulation patent by changing excipients or manufacturing pathway.
• A method-of-use patent is harder to design around if it matches label wording that the generic must seek to substitute.

---

What Orange Book status applies to provitamin D2 drugs, and what patents are listed?

Featured snippet answer: In the US, DHT products typically appear with a limited list of Orange Book patents for composition/formulation and sometimes method-of-use, reflecting legacy product families and any later reformulation.

Orange Book mapping logic for DHT

• Identify:
  • Listed drug name
  • Dosage form and strength
  • Patent numbers and expiration dates
  • Exclusivity (if any) associated with the listed drug
• Then link each patent number to:
  • claim type (composition, method of use, process)
  • enforcement likelihood (based on whether it has been litigated, cited in disputes, or treated as essential)

Practical implication for generic entry

• Orange Book patents are the core gating items for Paragraph IV challenges.
• If a product has “cleared” major Orange Book patents, generic applicants can pursue timely ANDA approval with standard bioequivalence, avoiding litigation.

---

Which generic entry risks exist for dihydrotachysterol, including Paragraph IV strategy?

Featured snippet answer: For mature DHT, Paragraph IV risk usually focuses on whether any still-listed patents cover the exact dosage form/strength and whether method-of-use claims align with the applicant’s proposed label.

Generic pathway risks

1. Paragraph III/IV vs. “carve-out” labels
   • If listed patents include method-of-use, challengers may need label carve-outs.
2. Formulation and manufacturing IP
   • Even with “design around,” a challenger may face enforcement if patents cover essential process steps or critical impurity controls.
3. Market access and switching
   • Even after patent expiry, payers may delay switching if the legacy product has established contracts.

Settlement-driven entry risk

If the brand holder has previously settled ANDA challenges, later entrants face:

• “delayed entry” terms
• cross-licensing of specific process claims
• continued brand manufacturing exclusivity for some strengths

---

What provitamin D2 patent litigation affects generic launch timing?

Featured snippet answer: In legacy vitamin D analogs, litigation tends to concentrate on product-specific patents (composition/process) rather than the original compound, and settlements typically drive entry timing more than long trials.

Litigation patterns that matter for DHT

• Challenges against Orange Book-listed patents
• Settlement agreements with:
  • “at risk” entry dates
  • payment-for-delay style terms where applicable under historical practice
  • stipulations on label or formulation non-infringement

How to translate litigation outcomes into launch timing

• Identify:
  • case disposition date (dismissal, summary judgment, settlement)
  • specific patents covered by the dispute
  • whether settlement ties to an exclusivity date or an agreed design-around

---

How does dihydrotachysterol compare with other vitamin D analogs on patent barriers?

Featured snippet answer: Competing vitamin D analogs (calcitriol, alfacalcidol, ergocalciferol formulations) have their own estates, but many are older and face similar post-primary-expiry dynamics. Patent barriers for DHT are typically comparable to other legacy vitamin D analogs, with the most persistent barriers being formulation/process or label-specific use claims.

Competitive substitution dynamics

• DHT competes through:
  • clinician preference in hypoparathyroidism settings
  • dosing schedule practicality
  • availability and wholesaler inventory
• Patent barriers matter less than:
  • payer formularies
  • clinical pathway norms
  • generic switch inertia

Relative risk framing for investors and litigators

• If DHT’s remaining active patents are narrow, substitution by other generics or analogs can neutralize any remaining exclusivity economics.
• If DHT has active formulation/process patents tied to scarcity or complex manufacturing, generic launch could be delayed even after expiry of broader claims.

---

Which companies hold or license the provitamin D2 patent estate?

Featured snippet answer: DHT’s modern market is typically supported by legacy brand holders and multiple generic suppliers across different countries; patent ownership often sits with the original innovator or with successors who acquired portfolios during consolidation.

Ownership structure to verify in patent prosecution and litigation files

• Original assignee and successor entities
• Licensing to local manufacturers for specific markets
• Rights transfers reflected in:
  • assignment records
  • EPO register changes
  • court docket updates

What matters for deal-making

• Whether remaining active patents are:
  • held centrally (facilitates cross-licensing)
  • fractured by geography and assignee (complicates licensing and enforcement)

---

What formulations are protected for provitamin D2 compounds?

Featured snippet answer: For DHT, formulation protection usually covers specific dosage forms and excipient systems intended to improve stability, dosing uniformity, or manufacturing reliability.

Formulation patent targets

• Tablet/capsule strength-specific compositions
• Vehicle systems for oily solutions or liquid forms (where used)
• Stability improvements impacting shelf life and impurity profiles

Why formulation patents can still matter after compound expiry

• A generic can often match API specification, but if the brand’s patent covers a specific formulation architecture, the generic must:
  • redesign excipients and process
  • demonstrate non-infringement under doctrine-specific tests
  • or negotiate a license

---

What manufacturing method patents could block generic dihydrotachysterol?

Featured snippet answer: Manufacturing method patents can impede generic entry when they claim specific crystallization, purification, or impurity-limiting process steps that are difficult to replicate without triggering infringement.

Typical process claim hooks

• Controlled crystallization conditions
• Purification steps reducing specific impurities
• Particle size and uniformity controls tied to bioavailability consistency
• Methods establishing impurity profiles that match regulatory release specs

How this changes the generic calculus

• A generic can choose not to litigate by:
  • altering its process design
  • sourcing from a contract manufacturer under a different process
• If the process claims are strong and have been asserted, the challenger’s “time to design around” becomes the main cost driver.

---

When do biosimilar pathways apply to provitamin D2 compounds?

Featured snippet answer: Biosimilar pathways do not apply because DHT is a small molecule, not a biologic.

Implication

• Competitive threats are generic ANDAs (or non-US equivalents) rather than biosimilar development.

---

What is the commercial exposure of the provitamin D2 market to patent expiry and generic launches?

Featured snippet answer: Commercial exposure is concentrated in branded DHT revenue and in specific strengths where formulation/process patents remain active. Once core Orange Book patents expire, generic entry risk rises sharply and margin pressure follows from pricing dynamics in endocrine therapy.

Revenue exposure mechanics

• Branded revenue is most vulnerable when:
  • listed patents expire cleanly without remaining narrow formulation barriers
  • payers support automatic substitution or preferred generic status
• Even with patent barriers, supply reliability and distribution contracts can delay substitution.

Market dynamics by segment

• Hypoparathyroidism specialists and long-term clinics tend to switch slower than acute-care settings.
• Primary care may switch based on formulary changes rather than brand-prescriber preference.

---

Key takeaways

• The provitamin D2 drug class is effectively a DHT-focused landscape in mature markets.
• Patent protection is typically residual post-primary expiry and most often concentrates in formulation and manufacturing/process claims tied to specific dosage forms and strengths.
• Orange Book-listed patents (US) remain the principal gating items for generic Paragraph IV strategy.
• For DHT, biosimilar risk is not applicable; the competitive question is generics versus legacy product switching dynamics.
• Litigation and settlement patterns, when present, typically determine launch timing more than the underlying breadth of the original compound IP.

---

FAQs

1. What types of claims are most common in remaining dihydrotachysterol patents after compound expiry?
2. How do formulation patents affect generic substitution for dihydrotachysterol strengths and dosage forms?
3. What is the Paragraph IV challenge process for dihydrotachysterol under the US Orange Book framework?
4. Do method-of-use claims on vitamin D analogs create label carve-out requirements for generic ANDAs?
5. What non-IP factors most influence how quickly payers switch patients from branded DHT to generics?

---

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. US FDA.
2. FDA. Guidance for Industry: Paragraph IV Certification and Notice Requirements (ANDA). US FDA.